Sanofi announces the publication by the NEJM of phase III data from the XTEND-Kids study, showing that Altuviiio has the potential to transform the therapeutic management of children under 12 years of age with severe hemophilia A.

The once-weekly dose achieves sustained levels of factor VIII expression in these patients, and confers highly effective protection against bleeding, without leading to the development of factor VIII inhibitors.

Altuviiio is approved for routine prophylaxis, on-demand treatment of bleeding episodes and peri-operative (surgical) management of adults and children with hemophilia A.

Copyright (c) 2024 CercleFinance.com. All rights reserved.